Messenger RNA technology, soon to be applied to diseases other than Covid-19?
Pfizer announced Monday that it has conducted the first human clinical trials of a Messenger RNA influenza vaccine.
The American pharmaceutical company made these first injections in the United States in healthy people aged 65 to 85 years.
The test should make it possible to assess the safety of a dose of this new vaccine, as well as its immunogenicity (ability to cause an immune reaction).
It will include a few hundred participants, according to clinical trial details posted on a US government site.
The American biotechnology company Moderna also declared that it had launched trials of such a product in early July.
290,000 to 650,000 flu deaths per year
Current influenza vaccines use inactivated viruses - a process that takes a long time to make.
The target strains of the constantly evolving virus must therefore be chosen for the development of vaccines about six months before the start of the seasonal epidemic.
The effectiveness of the vaccines used at the moment is generally 40% to 60%.
"The flexibility of messenger RNA technology and its rapid production could potentially allow better association with the strain (of the circulating virus), greater reliability of supply, and the opportunity to improve effectiveness of current influenza vaccines, ”says Pfizer in its press release.
The World Health Organization estimates that influenza is responsible for around 3 to 5 million cases of serious illness each year, and 290,000 to 650,000 deaths.
In addition to influenza, Pfizer said it plans to study the use of messenger RNA technology against other respiratory viruses, as well as against genetic diseases or cancers.
Health
United States: The Covid-19 has now killed more people than the Spanish flu
Health
Coronavirus: Pfizer starts clinical trial for preventive use of its anti-Covid pill
Flu
Pfizer-BioNTech
Pharmaceutical industry
Health
Vaccine
Vaccination